Biofortuna
Biofortuna to Further Commercialize Genotyping Assays With £1.6M Financing
The company said that the funds will allow it to take its ReadyPlex rapid blood group genotyping assays into clinical trials and commercialization.
Biofortuna Expands Immunoassay Manufacturing
The expansion is motivated by increasing market demands and the success of current customer immunoassay development projects.